2011年 · 第50卷第10期

Multiple myeloma (MM) is a malignant proliferative disease of plasma cells in which clonal plasma cells in the bone marrow abnormally proliferate and secrete monoclonal immunoglobulins or fragments thereof (M protein), resulting in damage to related organs or tissues (ROTI). The common clinical manifestations are bone pain, anemia, renal insufficiency and infection.

The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2011) finally met with readers. This edition of the guide has been updated with reference to relevant international guidelines or consensus. In the diagnostic section, according to the diagnostic criteria of the WHO classification of hematopoietic and lymphoid tissue tumors, the description of the primary criteria and secondary criteria in the 2008 edition was deleted, emphasizing that multiple myeloma (MM) can be diagnosed if the presence of clonal plasma cells can be confirmed on the basis of the discovery of serum and/or urine M components. If it is accompanied by damage to the associated organ or tissue, symptomatic MM is diagnosed and needs immediate treatment. The diagnosis of MM has evolved from simple cell morphology diagnosis to a comprehensive diagnosis mode combining cell biology and clinical medicine. The author believes that the following three problems should be paid attention to in the diagnosis of MM.

The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2011) have been released. Correct mastery and application of this guideline is of great significance for the standardized treatment of multiple myeloma (MM). The author will make an interpretation of the treatment part of the guideline.

The efficacy criteria of the Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2011) were developed with reference to the efficacy criteria of the European Bone Marrow Transplantation Collaborative Group (EBMT) and the International Myeloma Working Group (IMWG). EBMT standard is more widely applied, and IMWG standard is based on EBMT standard with some modifications and supplements. In 2011, the IMWG Expert GroupBloodPublished the latest consensus on efficacy judgment criteria, and made a series of revisions to the IMWG criteria.